GC Cell Corporation (KOSDAQ: 144510)

Market Cap	472.60B
Revenue (ttm)	184.44B
Net Income (ttm)	-10.71B
Shares Out	15.03M
EPS (ttm)	-713.04
PE Ratio	n/a
Forward PE	n/a
Dividend	100.00 (0.30%)
Ex-Dividend Date	n/a

Volume	60,572
Open	33,300
Previous Close	33,200
Day's Range	31,100 - 33,550
52-Week Range	26,500 - 48,800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 752
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510